Table 1: Preclinical model systems for theratyping.
Model system | Source | Level of advancement | Most common uses |
---|---|---|---|
Transient CFTR expression in heterologous cell lines |
Established cell lines |
high | Characterize CFTR variants and CFTR biology |
Stable CFTR transduction in cell lines |
Established cell lines |
high |
HTS screening, evaluate common and rare CFTR variants in standardized system |
Human bronchial airway epithelial (HBE) planar cultures |
Lung explant |
high |
Validation of CFTR modulation in primary human cells, assess downstream effects (e.g. mucocilary clearance, airway surface liquid height) |
Rectal organoids |
Rectal biopsy |
moderate |
Validation of CFTR modulation in primary human cells, and patient-specific responses to modulators (fluid secretion) |
Duodenal enteroids | Duodenal biopsy |
low | Similar to rectal organoids Above |
HBE planar cultures from brush |
Bronchial brush |
low |
Similar to HBEs from lung explant, and patient-specific responses to modulators (ion transport) |
Human nasal epithelial (HNE) planar cultures from brush |
Nasal brush |
low |
Similar to HBEs from lung explant, and patient-specific responses to modulators (ion transport) |
HNE spheres |
Nasal brush |
low |
Similar to HBEs from lung explant, and patient-specific responses to modulators (fluid transport) |
Induced pluripotent stem cells (iPSCs) |
Blood |
low |
Differentiation into CFTR- expressing epithelial cells and tissues |